Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC)
It is still not possible for all patients with early breast cancer to be cured. Even when they respond well to initial therapy, there exists a substantial risk for recurrence, sometimes after several years. With the availability of cyclin-dependent kinase (CDK) 4/6 inhibitors the role of adjuvant th...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2025-01-01
|
| Series: | South Asian Journal of Cancer |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1791768 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849392863443419136 |
|---|---|
| author | Purvish M. Parikh Amish Vora Rajan Yadav Akhil Kapoor Tarini Sahoo Senthil Rajappa Govind Babu Kanakashetty M. Vamshi Krishna Ghanashyam Biswas Ankur Bahl Nikhil Ghadyalpatil Thirumalairaj Raja Jyoti Bajpai Amol Akhade Randeep Singh Shyam Aggarwal Maheboob Basade S.H. Advani |
| author_facet | Purvish M. Parikh Amish Vora Rajan Yadav Akhil Kapoor Tarini Sahoo Senthil Rajappa Govind Babu Kanakashetty M. Vamshi Krishna Ghanashyam Biswas Ankur Bahl Nikhil Ghadyalpatil Thirumalairaj Raja Jyoti Bajpai Amol Akhade Randeep Singh Shyam Aggarwal Maheboob Basade S.H. Advani |
| author_sort | Purvish M. Parikh |
| collection | DOAJ |
| description | It is still not possible for all patients with early breast cancer to be cured. Even when they respond well to initial therapy, there exists a substantial risk for recurrence, sometimes after several years. With the availability of cyclin-dependent kinase (CDK) 4/6 inhibitors the role of adjuvant therapy has improved, and so has the chance of cure. These consensus guidelines will ensure that the community oncologist will be able to take the right decision for their patient. The expert committee shares their real-world experience as well as the consensus voting results. Patients eligible for adjuvant therapy with CDK4/6 inhibitors should start that treatment at the earliest. Based on current published data, abemaciclib is the preferred CDK4/6 inhibitor that should be used in eligible patients (unless contraindicated). To ensure optimal dose intensity and adherence to treatment schedule, use of literature and patient information material can improves compliance. Treatment modification requires early reporting of adverse effects, a responsibility of the patient and caregiver (relatives). |
| format | Article |
| id | doaj-art-0db26f0ba56a4d05baf8774a1efb2405 |
| institution | Kabale University |
| issn | 2278-330X 2278-4306 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | South Asian Journal of Cancer |
| spelling | doaj-art-0db26f0ba56a4d05baf8774a1efb24052025-08-20T03:40:41ZengThieme Medical and Scientific Publishers Pvt. Ltd.South Asian Journal of Cancer2278-330X2278-43062025-01-01140104505210.1055/s-0044-1791768Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC)Purvish M. Parikh0Amish Vora1Rajan Yadav2Akhil Kapoor3https://orcid.org/0000-0001-6006-2631Tarini Sahoo4Senthil Rajappa5Govind Babu Kanakashetty6https://orcid.org/0000-0002-1303-2226M. Vamshi Krishna7Ghanashyam Biswas8Ankur Bahl9Nikhil Ghadyalpatil10Thirumalairaj Raja11Jyoti Bajpai12Amol Akhade13Randeep Singh14Shyam Aggarwal15Maheboob Basade16S.H. Advani17Department of Clinical Hematology, Sri Ram Cancer Center, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, IndiaDepartment of Medical Oncology, Hope Oncology Center, New Delhi, IndiaDepartment of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, IndiaDepartment of Medical Oncology, Mahamana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, Uttar Pradesh, IndiaDepartment of Medical Oncology, Silverline Hospital, Bhopal, Madhya Pradesh, IndiaDepartment of Medical Oncology, Basavatarakam Indo American Cancer Hospital, Hyderabad, Telangana, IndiaDepartment of Medical Oncology, St. John's Medical College and Hospital, Bengaluru, Karnataka, IndiaDepartment of Medical Oncology, AIG Hospital, Hyderabad, Telangana, IndiaDepartment of Medical Oncology, Sparsh Hospitals and Critical Care Pvt Ltd., Bhubaneswar, Orissa, IndiaDepartment of Medical Oncology, Fortis Medical, Gurugram, Haryana, IndiaDepartment of Medical Oncology, Yashoda Hospital, Hyderabad, Telangana, IndiaDepartment of Medical Oncology, Apollo Hospital, Chennai, Tamil Nadu, IndiaDepartment of Medical Oncology, Apollo Hospital, Navi Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Bethany Hospital, Thane, Maharashtra, IndiaDepartment of Medical Oncology, Narayana Health, Gurugram, Haryana, IndiaDepartment of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, IndiaDepartment of Medical Oncology, Saifee Hospital, Mumbai, Maharashtra, IndiaDepartment of Medical Oncology, Sushrusha Hospital, Mumbai, Maharashtra, IndiaIt is still not possible for all patients with early breast cancer to be cured. Even when they respond well to initial therapy, there exists a substantial risk for recurrence, sometimes after several years. With the availability of cyclin-dependent kinase (CDK) 4/6 inhibitors the role of adjuvant therapy has improved, and so has the chance of cure. These consensus guidelines will ensure that the community oncologist will be able to take the right decision for their patient. The expert committee shares their real-world experience as well as the consensus voting results. Patients eligible for adjuvant therapy with CDK4/6 inhibitors should start that treatment at the earliest. Based on current published data, abemaciclib is the preferred CDK4/6 inhibitor that should be used in eligible patients (unless contraindicated). To ensure optimal dose intensity and adherence to treatment schedule, use of literature and patient information material can improves compliance. Treatment modification requires early reporting of adverse effects, a responsibility of the patient and caregiver (relatives).http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1791768targeted therapyIDFShigh riskregulatory approval |
| spellingShingle | Purvish M. Parikh Amish Vora Rajan Yadav Akhil Kapoor Tarini Sahoo Senthil Rajappa Govind Babu Kanakashetty M. Vamshi Krishna Ghanashyam Biswas Ankur Bahl Nikhil Ghadyalpatil Thirumalairaj Raja Jyoti Bajpai Amol Akhade Randeep Singh Shyam Aggarwal Maheboob Basade S.H. Advani Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC) South Asian Journal of Cancer targeted therapy IDFS high risk regulatory approval |
| title | Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC) |
| title_full | Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC) |
| title_fullStr | Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC) |
| title_full_unstemmed | Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC) |
| title_short | Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC) |
| title_sort | consensus guidelines for the use of cyclin dependent kinase cdk 4 6 inhibitors in the management of hormone receptor positive hr ve her2 ve early breast cancer ebc |
| topic | targeted therapy IDFS high risk regulatory approval |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1791768 |
| work_keys_str_mv | AT purvishmparikh consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT amishvora consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT rajanyadav consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT akhilkapoor consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT tarinisahoo consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT senthilrajappa consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT govindbabukanakashetty consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT mvamshikrishna consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT ghanashyambiswas consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT ankurbahl consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT nikhilghadyalpatil consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT thirumalairajraja consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT jyotibajpai consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT amolakhade consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT randeepsingh consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT shyamaggarwal consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT maheboobbasade consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc AT shadvani consensusguidelinesfortheuseofcyclindependentkinasecdk46inhibitorsinthemanagementofhormonereceptorpositivehrveher2veearlybreastcancerebc |